Nails PsO Study

Study of the effects of secukinumab on nail psoriasis

Type

Interventional – treatment

Open-label. The study drug is secukinumab (Cosentyx), which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis and psoriatic arthritis in adults.

Purpose

Nail psoriasis can cause significant functional impairment and emotional distress and may be associated with development of psoriatic arthritis (PsA). However, little is known about nail psoriasis, including how to measure it and how it responds to systemic treatment.

The purpose of this study to determine how psoriatic nail disease is affected by secukinumab (Cosentyx), an FDA-approved systemic treatment for psoriasis and psoriatic arthritis. The study will also identify predictors of nail response to treatment and examine a range of patient-reported outcomes and imaging measurements for nail disease.

The goal is to gain insights into nail disease response to treatment and identify markers that can better guide treatment of psoriatic nail disease in the future.

Eligibility

You may be eligible for this study if you:

• Are aged 18-85;
• Have active skin psoriasis or have in the past;
• Have active psoriatic nail disease;
• Have not been diagnosed with psoriatic arthritis (PsA); and
• Have not taken an IL17i in the past.

Participation

You will be followed over the course of 24 weeks, with in-person study visits every 4 weeks. In-person study visits will consist of full skin, nail, and joint examinations as well as study drug injections.

You will have an MRI and ultrasound of the hands at your Baseline and Week 4 visits.

You will complete questionnaires online regularly throughout the study to tell us how you’re doing.

You will receive compensation for your time at the in-person study visits.